J&J Device Sales Fall

The healthcare giant reported worldwide medical devices sales of $27.5 billion for the full-year 2014, a decrease of 3.4 percent versus the prior year.

Johnson & Johnson’s medical device business posted decreased sales for both the fourth quarter and 2014, on top of the effects of the strong dollar that pushed down sales for the healthcare giant.

The New Brunswick, N.J.-based healthcare giant reported worldwide medical devices sales of $27.5 billion for the full-year 2014 represented a decrease of 3.4 percent versus the prior year consisting of an operational decrease of 1.6 percent and a negative currency impact of 1.8 percent.

Domestic sales decreased 4.3 percent; international sales decreased 2.7 percent, which reflected an operational increase of 0.5 percent and a negative currency impact of 3.2 percent.

Excluding the net impact of acquisitions and divestitures, on an operational basis, worldwide sales increased 1.6 percent, domestic sales decreased 0.6 percent and international sales increased 3.5 percent. The divestiture of the Ortho-Clinical Diagnostics business was completed in June.

In prepared remarks, Chairman and CEO Alex Gorsky said: “2014 was a strong year for Johnson & Johnson, as we delivered solid financial results while continuing to make investments to accelerate growth for the long term. We have built significant momentum in our pharmaceutical business, are realizing the benefits of innovation, scale and breadth in our medical devices business and are continuing our market leadership with iconic brands in our consumer business.”

Primary contributors to operational growth were our broad portfolio of orthopedic products; Biosense Webster’s electrophysiology products in the Cardiovascular Care business; and bio-surgicals and international sales of energy products in the Specialty Surgery business. During the quarter, the FDA approved the Animas® Vibe™ insulin pump and Continuous Glucose Monitoring system for the management of insulin-requiring diabetes in adults ages 18 and older.

Related Articles

  • Daniel Lace

    “We are honored to have Dr. Lace, who is widely recognized as one of the industry’s most trusted reimbursement experts, leading our new division. He will also support all our services as our CMO.”

  • Hand holding globe - diversity

    “Approaches to Increasing Diversity in Clinical Research and Addressing Health Inequities” offers key recommendations for device manufacturers and developers on steps they can take to increase diversity in clinical research and address health equity.

  • Sanobar Syed

    Market research and forecasting help ensure that you are investing in a device or drug that is needed and will be well received. In this article, Sanobar Syed, Associate Director of Forecasting, Market Insights and Strategies, BeiGene, highlights strategies to…

  • John Schwope

    AI not only improves data collection and analysis, it impacts which products are engaged in clinical trials, determines necessary medical criteria, helps design the trials and can even choose the best participating facilities. The result is, organizations that leverage AI…